Shopping Cart
Remove All
Your shopping cart is currently empty
CK7
Copy Product Info
🥰Excellent
Catalog No. T9615Cas No. 507487-89-0
CK7 (a Cdk2/9 inhibitor) is crucial in synthesizing Nek1 inhibitors [BSc5231] and [BSc5367].
CK7
Copy Product Info🥰Excellent
Purity: 99.54%
Catalog No. T9615Cas No. 507487-89-0
CK7 (a Cdk2/9 inhibitor) is crucial in synthesizing Nek1 inhibitors [BSc5231] and [BSc5367].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 5 mg | $123 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $396 | In Stock | In Stock | |
| 50 mg | $619 | In Stock | In Stock | |
| 100 mg | $953 | In Stock | In Stock | |
| 200 mg | $1,280 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $135 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.54%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
CK7 AI Summary
CK7 exhibits bioactivities related to the inhibition of various cyclin-dependent kinases (CDKs), including CDK1, CDK2, CDK4, CDK5, CDK7, and CDK9, with low nanomolar or sub-nanomolar Ki values. It also shows inhibitory activity against Abl kinase and glycogen synthase kinase-3 beta (GSK3-beta). Beyond its kinase inhibitory properties, CK7 demonstrates anti-proliferative effects against human tumor cell lines, notably A549, HT-29, SaOS-2, MIAPaCa2, and A2780, with IC50 values ranging from 48.0 nM to 300.0 nM. Additionally, the compound induces cell cycle arrest in HCT116 cells at the G2/M phase at concentrations between 0.2 to 2.6 µM and shows limited effects on mitotic reduction, multinuclear reduction, and apoptosis in HeLa cells. It also produces thermal stabilization of proteins involved in cellular functions such as AMPK, CAMKs, CDKs, CK1s, and PAKs. Notably, CK7 demonstrates selectivity in inhibiting Aurora B and Aurora A kinases over CDK9 and CDK2. Furthermore, it exhibits toxicity in zebra fish embryos at a concentration of 1.5 µM, illustrating 100% lethality compared to the control group. This comprehensive bioactivity profile indicates that CK7 has potential therapeutic applications in modulating cell cycle control and cellular signaling pathways..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CK7 (a Cdk2/9 inhibitor) is crucial in synthesizing Nek1 inhibitors [BSc5231] and [BSc5367]. |
| Molecular Weight | 328.35 |
| Formula | C14H12N6O2S |
| Cas No. | 507487-89-0 |
| Smiles | Cc1nc(N)sc1-c1ccnc(Nc2cccc(c2)[N+]([O-])=O)n1 |
| Relative Density. | 1.490 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 12.5 mg/mL (38.07 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.09 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CK7 | purchase CK7 | CK7 cost | order CK7 | CK7 chemical structure | CK7 formula | CK7 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.